Keywords: Roche, German, Avastin, Pay-for-permance deal, AMNOG

Roche offers Germany a pay-for-performance deal on Avastin

Article | 31 October 2011

Print This

In Germany’s tight market for new and existing drugs to gain reimbursement, Swiss drug major Roche (ROG: SIX) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in